Nang Kuang Pharm Co Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NANG KUANG PHARM CO, and what generic and branded alternatives to NANG KUANG PHARM CO drugs are available?
NANG KUANG PHARM CO has five approved drugs.
Summary for Nang Kuang Pharm Co
| US Patents: | 0 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Nang Kuang Pharm Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nang Kuang Pharm Co | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;IV (INFUSION) | 206554-002 | Jun 7, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Nang Kuang Pharm Co | LINEZOLID | linezolid | SOLUTION;INTRAVENOUS | 207354-002 | Dec 20, 2016 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nang Kuang Pharm Co | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 212081-001 | Dec 16, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nang Kuang Pharm Co | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 207352-001 | May 25, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nang Kuang Pharm Co | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 207352-002 | May 25, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nang Kuang Pharm Co | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 204329-001 | Jun 16, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
